Diagnosis and Treatment of Gastrointestinal Stromal Tumor.
- Author:
Yoon Koo KANG
1
;
Dong Hoe KOO
Author Information
1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. ykkang@amc.seoul.kr
- Publication Type:Review
- Keywords:
GIST;
Diagnosis;
Treatment;
Imatinib;
Sunitinib;
Regorafenib
- MeSH:
Benzamides;
Gastrointestinal Stromal Tumors;
Gastrointestinal Tract;
Humans;
Indoles;
Korea;
Molecular Targeted Therapy;
Phenylurea Compounds;
Piperazines;
Protein-Tyrosine Kinases;
Pyridines;
Pyrimidines;
Pyrroles;
Imatinib Mesylate
- From:Korean Journal of Medicine
2013;85(4):341-353
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Gastrointestinal stromal tumors (GISTs), which are the most common mesenchymal tumors of the gastrointestinal tract, have represented an important advance in oncology field with the success of molecular targeted therapy. Since the approval of the tyrosine kinase inhibitor (imatinib) in 2002, the survival of patients with advanced GISTs has significantly increased. Accurate histopathologic diagnosis of GISTs and multidisciplinary approach has become more important for successful management of GISTs. Recently, imatinib has become a standard treatment even in adjuvant setting, and regorafenib has been approved for advanced GIST after failure of imatinib and sunitinib. This review presents here the updated results of relevant clinical studies for the further revision to the guideline of Korean GIST study group. We hope this review will help enhance the quality of diagnosis, treatment, and care of patients with GIST in Korea.
